Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis

Liver International

Volumn 23, Issue 6, 2003, Pages 476-483

  Nagaoka, Marcia R ^a   Kouyoumdjian, Maria ^a   Borges, Durval R ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cirrhosis; Inflammatory reaction; Liver fibrosis; Plasma kallikrein; Plasminogen activator tissue type; Receptor mediated endocytosis

Indexed keywords

CARBON TETRACHLORIDE; GADOLINIUM CHLORIDE; KALLIKREIN; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TURPENTINE OIL;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; ISOLATED LIVER; LIVER CIRRHOSIS; LIVER CLEARANCE; LIVER FIBROSIS; LIVER FUNCTION; LIVER PERFUSION; MALE; NONHUMAN; RAT; STIMULUS RESPONSE;

EID: 0347382433     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2003.00872.x     Document Type: Article

References (30)

1. Colman R W, Schmaier A H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
2. Borges D R, Webster M E, Guimarães A, Prado J L. Synthesis of prekallikrein and metabolism of plasma kallikrein by perfused rat liver. Biochem Pharmacol 1981; 30: 1065-9.
3. Borges D R, Kouyoumdjian M. The recognition site for hepatic clearance of plasma kallikrein is on its heavy chain and is latent on prokallikrein. J Hepatol 1992; 16: 115-21.
4. Díaz V M, Planagumà J, Thomson T M, Reventós J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002; 122: 806-19.
5. Wing L R, Hawksworth G M, Bennett B, Booth N A. Clearance of t-PA, PAI-1, and t-PA-PAI-I complex in an isolated perfused rat liver system. J Lab Clin Med 1991; 117: 109-14.
6. Narita M, Bu G, Herz J, Schwartz A L. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest 1995; 96: 1164-8.
7. Kuiper J, Otter M, Voorschuur A H, Van Zonneveld A J, Rijken D C, Van Berkel T J. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells. Thromb Haemost 1995; 74: 1298-304.
8. Hajjar K A, Reynolds C M. Alpha-fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J Clin Invest 1994; 93: 703-10.
9. Nagaoka M R, Kouyoumdjian M, Borges D R. Plasma kallikrein and tissue-type plasminogen activator compete for a common pathway into the liver. Immunopharmacology 1996; 32: 88-90.
10. Chavakis T, Pixley R A, Isordia-Salas I, Colman R W, Preissner K T. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 (PAI-1) function. J Biol Chem 2002; 277: 32677-82.
11. Brown N J, Nadeau J H, Vaughan D E. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522-5.
12. Pretorius M, Rosenbaum D, Vaughan D E, Brown N J. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003; 107: 579-85.
13. Jonsson J R, Clouston A D, Ando Y, Kelemen L I, Horn M J, Adamson M D, Purdie D M, Powell E E. Angiotensin converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-55.
14. Camacho-Lobato L, Borges DR. Early liver dysfunction in schistosomiasis. J Hepatol 1998; 29: 233-40.
15. Manoukian N, Borges D R. Prealbumin, prekallikrein and prothrombin in hepatoesplenic schistosomiasis: increased turnover of the clotting proteins? Rev Inst Med Trop São Paulo 1984; 26: 237-40.
16. Hayashi T, Kamogawa A, Ro S, Yamaguchi K, Kobayashi Y, Takahashi Y, Murayama M. Plasma from patients with cirrhosis increases tissue plasminogen activator release from vascular endothelial cells in vitro. Liver 1998; 18: 186-90.
17. Zhang L P, Takahara T, Yata Y, Furui K, Jin B, Kawada N, Watanabe A. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999; 31: 703-11.
18. International Guiding Principles for Biomedical Research Involving Animals by the Council for International Organizations of Medical Sciences (CIOMS). Geneva, Switzerland, 1985: 1-28.
19. Nagaoka M R, Kouyoumdjian M, Borges D R. The hepatic clearance of recombinant tissue-type plasminogen activator decreases after an inflammatory stimulus. Braz J Med Biol Res 2000; 33: 119-25.
20. Martins B, Kouyoumdjian M, Limaos E A, Borges D R. The clearance rate of plasma kallikrein by the liver increases during the acute-phase response to inflammation. Agents Actions 1992; 37: 111-3.
21. Sarphie T G, D'Souza N B, Deaciuc I V. Kupffer cell inactivation prevents lipopolysaccharide-induced structural changes in the rat liver sinusoid: an electron-microscopic study. Hepatology 1996; 23: 788-96.
22. Borges D R, Gordon A H, Guimarães J A, Prado J L. Rat plasma kallikrein clearance by perfused rat liver. Brazil J Med Biol Res 1985; 18: 187-94.
23. Bhunchet E, Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology 1993; 18: 1450-8.
24. Toledo C F, Kouyoumdjian M, Lanzoni V P, Borges D R. Plasma kallikrein clearance by the liver of chronic carbon tetrachloride-treated rats. J Gastroenterol Hepatol 1995; 10: 165-8.
25. Borges D R, Kouyoumdjian M. Chloramine T impairs the receptor-mediated endocytosis of plasma kallikrein by the liver. Agents Actions 1992; 38(Suppl.): 278-84.
26. Bode J G, Heinrich P C. Interleukin-6 signaling during the acute-phase response of the liver. In: Arias M, Boyer J L, Chisari F V, Fausto N, Schachter D, Shafritz D A, eds. The Liver: Biology and Pathobiology, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001; 565-80.
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
28. Borges D R, Nagaoka M R, Kouyoumdjian M. Liver clearance of tissue-type plasminogen activator and of plasma kallikrein in experimental cirrhosis. Hepatology 2000; 32: 529A.
29. Einarsson M, Smedsrod B, Pertoft H. Uptake and degradation of tissue plasminogen activator in rat liver. Thromb Haemost 1988; 59: 474-9.
30. Groszmann R J, Loureiro-Silva M R, Tsai M-H. The biology of portal hypertension. In: Arias M, Boyer J L, Chisari F V, Fausto N, Schachter D, Shafritz D A. The Liver: Biology and Pathobiology, 4th Edn. Philadelphia: Lippincott Williams & Wilkins, 2001; 679-97.